Retacrit

n engl j med 379;7 nejm.org August 16, 2018 695 logic agents. Although we would encourage evidence-based expansion of clinical… Expand

Comprehensive physicochemical characterization and biological assays are essential parts in assessing quality attributes of… Expand

ABSTRACT Introduction: There is an essential need for clinicians to understand the development and approval process of… Expand

The World Health Organization defines a biosimilar as "a biotherapeutic product which is similar in terms of quality, safety and… Expand

INTRODUCTION Erythropoiesis Stimulating Agents (ESA) are largely prescribed before dialysis stage to chronic kidney disease… Expand

President Barack Obama’s budget proposal for fiscal year 2012 reignites a controversy over biosimilar drugs that had been doused… Expand

ABSTRACTPurposeTo compare the quality of therapeutic erythropoietin (EPO) products, including two biosimilars, with respect to… Expand

This first phase of the first generation of modern biotechnology-derived protein drugs is now coming to an end with the… Expand

This year will see the first serious engagements in the biogenerics war, as two copycat versions of the world’s biggest-selling… Expand

Two patients with thalassemia minor and end-stage renal failure on hemodialysis were treated with epoetin zeta (Silapo®, Retacrit… Expand